Epix Medical President and COO Knight resigns

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Epix Medical Inc. this week announced the departure of President and COO Stephen C. Knight, M.D.

 Knight will remain with Epix through the company's NDA submission for MRI contrast agent MS-325. He eventually will assume the title of president for Fidelity Biosciences Group, a unit of Fidelity Investments.

 CEO Michael D. Webb will assume title of President of the Cambridge, Mass.-based company that specializes in pharmaceuticals for MRI.